๐Ÿ”ฅ J&J to Restructure Orthopedic Business After Medical Device Sales Mi

โ€“ Johnson & Johnson begins a 2-year restructuring program for its orthopedics business.

โ€“ Q3 medical device sales fell short of Wall Street expectations.

โ€“ The company plans to exit certain markets and discontinue some orthopedic products.

โ€“ Pressure on J&J's pharmaceutical unit intensifies as it targets $57 billion in drug sales by 2025.

โ€“ Fresh competition expected in 2025 for J&J's blockbuster psoriasis treatment, Stelara.

โ€“ J&J raises annual profit forecast despite challenges in medical devices.

โ€“ Weakness in the medical devices unit impacts stock performance.

โ€“ Stelara biosimilar rivals delayed until 2025 to boost sales.

โ€“ Sales of J&J's devices for abdomen surgeries affected by demand slowdown.

โ€“ J&J lacks scientific expertise to enter the obesity drug space.